226 related articles for article (PubMed ID: 31235749)
1. Small Molecule IL-36γ Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis.
Todorović V; Su Z; Putman CB; Kakavas SJ; Salte KM; McDonald HA; Wetter JB; Paulsboe SE; Sun Q; Gerstein CE; Medina L; Sielaff B; Sadhukhan R; Stockmann H; Richardson PL; Qiu W; Argiriadi MA; Henry RF; Herold JM; Shotwell JB; McGaraughty SP; Honore P; Gopalakrishnan SM; Sun CC; Scott VE
Sci Rep; 2019 Jun; 9(1):9089. PubMed ID: 31235749
[TBL] [Abstract][Full Text] [Related]
2. IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment.
Mercurio L; Morelli M; Scarponi C; Eisenmesser EZ; Doti N; Pagnanelli G; Gubinelli E; Mazzanti C; Cavani A; Ruvo M; Dinarello CA; Albanesi C; Madonna S
Cell Death Dis; 2018 Oct; 9(11):1104. PubMed ID: 30377293
[TBL] [Abstract][Full Text] [Related]
3. Interleukin (IL)-17/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses.
Mercurio L; Failla CM; Capriotti L; Scarponi C; Facchiano F; Morelli M; Rossi S; Pagnanelli G; Albanesi C; Cavani A; Madonna S
PLoS One; 2020; 15(4):e0222969. PubMed ID: 32352958
[TBL] [Abstract][Full Text] [Related]
4. IL-36γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease.
Friedrich M; Tillack C; Wollenberg A; Schauber J; Brand S
Inflamm Bowel Dis; 2014 Nov; 20(11):1891-901. PubMed ID: 25299544
[TBL] [Abstract][Full Text] [Related]
5. IL-36α and IL-36γ expressions in the differential diagnosis of palmoplantar psoriasis and palmoplantar eczema: A retrospective histopathologic and immunohistochemical study.
Erdem O; Leblebici C; Koku Aksu AE; Erdil D; Kara Polat A; Gürel MS
J Cutan Pathol; 2022 Jan; 49(1):42-48. PubMed ID: 34289144
[TBL] [Abstract][Full Text] [Related]
6. IL-36γ inhibits differentiation and induces inflammation of keratinocyte via Wnt signaling pathway in psoriasis.
Wang W; Yu X; Wu C; Jin H
Int J Med Sci; 2017; 14(10):1002-1007. PubMed ID: 28924372
[TBL] [Abstract][Full Text] [Related]
7. Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease.
Boutet MA; Bart G; Penhoat M; Amiaud J; Brulin B; Charrier C; Morel F; Lecron JC; Rolli-Derkinderen M; Bourreille A; Vigne S; Gabay C; Palmer G; Le Goff B; Blanchard F
Clin Exp Immunol; 2016 May; 184(2):159-73. PubMed ID: 26701127
[TBL] [Abstract][Full Text] [Related]
8. IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions.
D'Erme AM; Wilsmann-Theis D; Wagenpfeil J; Hölzel M; Ferring-Schmitt S; Sternberg S; Wittmann M; Peters B; Bosio A; Bieber T; Wenzel J
J Invest Dermatol; 2015 Apr; 135(4):1025-1032. PubMed ID: 25525775
[TBL] [Abstract][Full Text] [Related]
9. Identification of small-molecule elastase inhibitors as antagonists of IL-36 cytokine activation.
Sullivan GP; Davidovich PB; Sura-Trueba S; Belotcerkovskaya E; Henry CM; Clancy DM; Zinoveva A; Mametnabiev T; Garabadzhiu AV; Martin SJ
FEBS Open Bio; 2018 May; 8(5):751-763. PubMed ID: 29744290
[TBL] [Abstract][Full Text] [Related]
10. The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis.
Madonna S; Girolomoni G; Dinarello CA; Albanesi C
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284527
[TBL] [Abstract][Full Text] [Related]
11. Spinal IL-36γ/IL-36R participates in the maintenance of chronic inflammatory pain through astroglial JNK pathway.
Li Q; Liu S; Li L; Ji X; Wang M; Zhou J
Glia; 2019 Mar; 67(3):438-451. PubMed ID: 30578562
[TBL] [Abstract][Full Text] [Related]
12. IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis.
Bridgewood C; Fearnley GW; Berekmeri A; Laws P; Macleod T; Ponnambalam S; Stacey M; Graham A; Wittmann M
Front Immunol; 2018; 9():200. PubMed ID: 29535706
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity.
Towne JE; Renshaw BR; Douangpanya J; Lipsky BP; Shen M; Gabel CA; Sims JE
J Biol Chem; 2011 Dec; 286(49):42594-42602. PubMed ID: 21965679
[TBL] [Abstract][Full Text] [Related]
14. IL-36α from Skin-Resident Cells Plays an Important Role in the Pathogenesis of Imiquimod-Induced Psoriasiform Dermatitis by Forming a Local Autoamplification Loop.
Hashiguchi Y; Yabe R; Chung SH; Murayama MA; Yoshida K; Matsuo K; Kubo S; Saijo S; Nakamura Y; Matsue H; Iwakura Y
J Immunol; 2018 Jul; 201(1):167-182. PubMed ID: 29794016
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of IL-36 cytokines in folliculitis and eosinophilic pustular folliculitis.
Sato S; Chiba T; Nakahara T; Furue M
Australas J Dermatol; 2020 Feb; 61(1):e39-e45. PubMed ID: 31424098
[TBL] [Abstract][Full Text] [Related]
16. Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions.
Sachen KL; Arnold Greving CN; Towne JE
Cytokine; 2022 Aug; 156():155897. PubMed ID: 35679693
[TBL] [Abstract][Full Text] [Related]
17. Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36γ.
Ainscough JS; Macleod T; McGonagle D; Brakefield R; Baron JM; Alase A; Wittmann M; Stacey M
Proc Natl Acad Sci U S A; 2017 Mar; 114(13):E2748-E2757. PubMed ID: 28289191
[TBL] [Abstract][Full Text] [Related]
18. IL-17A synergistically enhances TLR3-mediated IL-36γ production by keratinocytes: A potential role in injury-amplified psoriatic inflammation.
Liu S; Wu F; Wu Z; Li Y; Zhang S; Yu N
Exp Dermatol; 2019 Mar; 28(3):233-239. PubMed ID: 30614571
[TBL] [Abstract][Full Text] [Related]
19. Interleukin (IL)-8 and IL-36γ but not IL-36Ra are related to acrosyringia in pustule formation associated with palmoplantar pustulosis.
Xiaoling Y; Chao W; Wenming W; Feng L; Hongzhong J
Clin Exp Dermatol; 2019 Jan; 44(1):52-57. PubMed ID: 29896852
[TBL] [Abstract][Full Text] [Related]
20. Development of a Topical Treatment for Psoriasis Targeting RORγ: From Bench to Skin.
Smith SH; Peredo CE; Takeda Y; Bui T; Neil J; Rickard D; Millerman E; Therrien JP; Nicodeme E; Brusq JM; Birault V; Viviani F; Hofland H; Jetten AM; Cote-Sierra J
PLoS One; 2016; 11(2):e0147979. PubMed ID: 26870941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
